Mather Group LLC. Has $2.04 Million Stock Position in Danaher Co. (NYSE:DHR)

Mather Group LLC. grew its position in Danaher Co. (NYSE:DHR) by 155.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,182 shares of the conglomerate’s stock after acquiring an additional 4,984 shares during the quarter. Mather Group LLC.’s holdings in Danaher were worth $2,043,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares during the period. Cercano Management LLC lifted its position in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after acquiring an additional 20,715 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after acquiring an additional 96,395 shares during the period. Donaldson Capital Management LLC grew its position in shares of Danaher by 5.8% in the first quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock valued at $367,000 after purchasing an additional 80 shares during the last quarter. Finally, Caden Capital Partners LP increased its position in Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR traded down $0.48 during mid-day trading on Tuesday, hitting $268.84. 2,763,612 shares of the company traded hands, compared to its average volume of 2,909,858. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $194.16 billion, a price-to-earnings ratio of 46.18, a PEG ratio of 4.62 and a beta of 0.83. The business has a 50-day moving average of $256.42 and a 200 day moving average of $251.43. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the company earned $2.05 EPS. As a group, equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. SVB Leerink upped their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Citigroup lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Royal Bank of Canada raised their price target on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $276.88.

Insider Buying and Selling

In other Danaher news, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders sold a total of 113,174 shares of company stock worth $29,775,644 over the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.